UREVO Announces Black Friday Sale 2026 with Its Biggest Discounts of the Year
REDMOND, Wash., Nov. 18, 2026 (GLOBE NEWSWIRE) -- UREVO, an everyday wellness technology brand, has announced its Black Friday Sale...
REDMOND, Wash., Nov. 18, 2026 (GLOBE NEWSWIRE) -- UREVO, an everyday wellness technology brand, has announced its Black Friday Sale...
-- ELEVATE-45-201 Cohort 2 (10 mg/kg) enrollment complete with data expected in H1 2027 -- BOSTON, Nov. 18, 2026 (GLOBE...
Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management...
Orally bioavailable KAT6A degraders demonstrated potent antiproliferative activity in diverse in vivo models of ER+/HER2- breast cancerKAT6A degradation was active...
INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case Mont-Saint-Guibert, Belgium – November...
Press release – No. 25 / 2026 Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered...
Four-year renewed commitment will help advance the development of much-needed products to prevent, diagnose, and treat dangerous bacterial infectionsHELLERUP, Denmark...
Pelabresib 144-week Phase III MANIFEST-2 data show sustained clinical effects in longest follow-up from a combination trial in first-line JAKi-naïve...
NORTHFIELD, Ill., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its secondary...
ERAS-0015 will be evaluated with PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer in Phase 1/2 trial BMS will sponsor the...
Los Angeles, California, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Portsmouth Square, Inc. (the “Company” or “Portsmouth”) announced financial results for...
MISSISSAUGA, Ontario, Nov. 17, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its consolidated financial results...
MISSISSAUGA, Ontario, Nov. 17, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce...
Diranersen slowed clinical decline by 38% on CDR-SB at two years (Week 96) with the 60 mg twice-yearly regimen, corresponding...
Participating KOLs include six leading physician experts representing vascular surgery, interventional cardiology, vascular medicine, and neurosurgery Webinar to take place...
IAPRD late-breaking poster shows MDS-UPDRS motor scores remained stable compared to baseline recorded at study entry with no disease progression...
- CytomX to receive $5 million preclinical milestone payment - - The CytomX and Regeneron collaboration began in 2022 and...
MINNEAPOLIS, Nov. 17, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing,...
MENLO PARK, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing...
WATERTOWN, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company...